Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Grant revenue	$ 24		$ 24
Sales	159	$ 77	407	$ 185
Total revenue	183	77	431	185
Cost of sales	106	41	275	106
Gross profit	77	36	156	79
Operating expenses:
Research and development	514	380	1,424	902
Selling, general and administrative	1,816	1,568	5,173	5,040
Total operating expenses	2,330	1,948	6,597	5,942
Net operating loss	(2,253)	(1,912)	(6,441)	(5,863)
Other income (expense):
Interest income	2		5	2
Interest expense	(2)	(7)	(10)	(22)
Payroll Protection Program loan forgiveness			650
Other income			22	18
Total other income		(7)	667	(2)
Net loss and comprehensive loss	(2,253)	(1,919)	(5,774)	(5,865)
Deemed dividend-warrant price protection-revaluation adjustment				414
Net loss attributable to common shareholders	$ (2,253)	$ (1,919)	$ (5,774)	$ (6,279)
Weighted average common shares outstanding - basic and fully diluted (in Shares)	12,190,257	3,398,832	10,850,197	2,593,288
Net loss per common share - basic and fully diluted (in Dollars per share)	$ (0.18)	$ (0.56)	$ (0.53)	$ (2.42)